Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ozagrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 known ✓ | P24557 | 14/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozagrel SCHEMBL28049244 | 1.00 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582827 | 1.00 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL27808192 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL4210 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL4211 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL1652693 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL36182 | 0.97 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL36183 | 0.97 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL10493936 | 0.96 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL10493930 | 0.96 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1010 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424132-A1 | ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR | BEIJING INNO MEDICINE CO., LTD. (CN) | 2024-12-26 | — | — | US | claimed |
| CN-221234322-U | Storage device of ozagrel sodium injection | 安徽诚联生物医药有限公司 | 2024-06-28 | — | — | CN | claimed |
| EP-4382094-A1 | ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR | Beijing Inno Medicine Co., Ltd. (CN) | 2024-06-12 | — | — | EP | claimed |
| CN-114371250-B | Method for determining acetate in ozagrel sodium bulk drug | 武汉九州钰民医药科技有限公司 | 2024-05-14 | — | — | CN | claimed |
| US-20240148913-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| CN-117471014-B | Ultra-high performance liquid chromatography detection method for potential genotoxic impurities in ozagrel bulk drug | 北京哈三联科技有限责任公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117750943-A | Targeted atherosclerosis liposome nano-carrier delivery system and preparation method thereof | 北京茵诺医药科技有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-117471014-A | Ultra-high performance liquid chromatography detection method for potential genotoxic impurities in ozagrel bulk drug | 北京哈三联科技有限责任公司 | 2024-01-30 | — | — | CN | claimed |
| CN-116942850-B | Nanometer drug delivery system for vulnerable plaque | 北京茵诺医药科技有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-116650477-B | Pharmaceutical composition containing ozagrel sodium for resisting platelet aggregation and preparation method thereof | 黑龙江迪龙制药有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-101397272-A | Method for preparing ozagrel sodium crystal | HAINAN KAIBI PHARMACEUTICAL CO (CN) | 2009-04-01 | — | — | CN | claimed |
| CN-1751751-A | Immediate dispensing infusion | HUABEI PHARMACEUTICAL GROUP CO (CN) | 2006-03-29 | — | — | CN | claimed |
| CN-1663569-A | Fructose injection for cardiovascular medicine | YANG XIHONG (CN) | 2005-09-07 | — | — | CN | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| CN-1568977-A | Sodium ozagrel for injection and preparation thereof | DUAN YAJUN (CN) | 2005-01-26 | — | — | CN | claimed |
| CN-1559613-A | Medicinal invert sugar injection | 杨喜鸿 | 2005-01-05 | — | — | CN | claimed |
| US-20040242565-A1 | Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-12-02 | — | — | US | claimed |
| CN-1546021-A | Oral liquid of sodium ozagrel and its application | 长春精优药业股份有限公司 | 2004-11-17 | — | — | CN | claimed |
| EP-1426051-A1 | MEDICINAL COMPOSITION FOR PREVENTION OF OR TREATMENT FOR CEREBROVASCULAR DISORDER AND CARDIOPATHY | Asahi Kasei Kabushiki Kaisha (JP) | 2004-06-09 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242565-A1 | Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy | ADORA1, ATP1A2, ATP2A1 | TBXAS1 497/4885CYP1A2 376/4885USP2 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.